Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner
- 1 September 2001
- journal article
- clinical trial
- Published by Elsevier in Atherosclerosis
- Vol. 158 (1) , 183-193
- https://doi.org/10.1016/s0021-9150(01)00410-5
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients witb hypercholesterolemiaThe American Journal of Cardiology, 1997
- A brief review paper of the efficacy and safety of atorvastatin in early clinical trialsAtherosclerosis, 1997
- A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulinAtherosclerosis, 1997
- Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemiaJAMA, 1996
- Identification and Characterization of a New Human Gene (APOC4) in the Apolipoprotein E, C-I, and C-II Gene LocusGenomics, 1995
- Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapyAtherosclerosis, 1995
- Effect of apolipoprotein E polymorphism and Xbal polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non‐familial hypercholesterolaemiaJournal of Internal Medicine, 1991
- Effects of probucol on plasma lipids and lipoproteins in familial hypercholesterolemic patients with and without apolipoprotein E4Atherosclerosis, 1990
- Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemiaAtherosclerosis, 1990
- The LDL–receptor–related protein, LRP, is an apolipoprotein E-binding proteinNature, 1989